About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« A Lovely Petite Compound | Main | November Conference on Drug Discovery in Boston »

October 3, 2012

AstraZeneca Stops Buying Its Own Stock

Email This Entry

Posted by Derek

So after all the talking we've done around here about stock buybacks in the pharma world, it's worth noting that the new CEO of AstraZeneca has halted their program. Naturally, that has people talking about what they're going to use the money for otherwise - that is, what company they're going to buy. But it's interesting to see a public mention of the buyback program hitting the brakes like this. . .

Comments (2) + TrackBacks (0) | Category: Business and Markets


1. Anonymous on October 3, 2012 9:18 PM writes...

After the aquisition, Pascal Soriot became CEO of Genentech, replacing Art Levinson. He didn't last long (WHY???) and moved back to Roche in Basel as COO. Now he's at AZ. What went wrong over at Roche. Any thoughts??

Permalink to Comment

2. Kissthechemist on October 5, 2012 5:58 AM writes...

The sum total of my knowledge of financial markets can be written on a nanotube, but for me, one driving force in the recent decline in big pharma is the instability - the constant changes in direction, often after mergers and aquisitions, and its demoralising and demotivating effects on the workers at the research coal-face, those who keep their jobs, that is.

Pharma is a marathon, not a sprint, but a lot of comapnies won't play it that way (eg the brand new pole of excellence that shuts it's doors permanantly inside 5 years).

The money theme keeps coming up here recently and I'm glad, 'cos there's lots of it around in Pharma being used for things other than turning it into a pipeline. Its clear the way we do research has to evolve but the idea floated the other day by Andrew Lo and friends, for example, is starting to look like its really worth trying.

Just for once, I'd like to see a major company trying something other than stock buy backs and aquisitions to feed the pipeline. Maybe it's time has come?

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry